Immunotherapy combo before & after surgery for head and neck cancer
Part of Cancer clinical trials.
This trial tests whether combining an immunotherapy drug (camrelizumab) with another targeted therapy or chemotherapy given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. It aims to see if this approach is more effective than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the head and neck (not nasopharyngeal cancer).
- Your cancer is at a locally advanced stage (stage III or IVb, depending on the exact type).
- You have not had any prior treatment (like chemo, radiation, or immunotherapy) for this cancer.
- You are willing and able to undergo surgery for your cancer.
- You are in good overall health (ECOG score 0 or 1) and your major organs (blood, liver, kidneys) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—camrelizumab (an immunotherapy) and dalpiciclib (a targeted therapy)—given before surgery for head and neck squamous cell carcinoma that can be removed. The goal is to see if this combination helps shrink the tumor and improves outcomes.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.